Exploration of the regional effects of colchicine in the LoDoCo2 trial - 10/11/24
, Stefan Nidorf, MD c, Arend Mosterd, MD d, e, Aernoud Fiolet, MD e, f, John Eikelboom, MBBS g, Sean O'Halloran, PhD k, l, David Joyce, MD k, l, Astrid Schut, MSc d, Jan Tijssen, PhD h, Jan H. Cornel, MD d, i, j, Kevin Murray, PhD a, b, Peter Thompson, MD c, mABSTRACT |
Background |
The Low Dose Colchicine 2 (LoDoCo2) trial randomized 5,522 patients with chronic coronary disease to colchicine 0.5mg daily or placebo in a 1:1 ratio and demonstrated the cardiovascular benefits of colchicine. In the trial, which was conducted in Australia and The Netherlands, a prespecified subgroup analysis suggested a difference in magnitude of treatment effect of colchicine by region (Australia: HR 0.51; 95% CI 0.39-0.67 vs The Netherlands: HR 0.92; 95% CI 0.71-1.20). The aim of this study was to explore possible explanations for the apparent difference in magnitude of treatment effect of colchicine by region in the LoDoCo2 trial.
Methods |
The analysis explored potential determinants of variations in the magnitude of effectiveness of colchicine treatment across the regions. This included investigating differences in investigational product, clinical characteristics, concurrent medical therapies and the duration of follow-up using a range of statistical techniques, including sub-group, landmark and effect modification analyses.
Results |
No differences were found in the colchicine product used in each region. Despite minor differences observed in baseline clinical characteristics and concomitant therapies, the effect modifier analyses demonstrated that these factors did not explain the difference in magnitude of treatment effect of colchicine by region. Randomization in Australia began more than 2 years before The Netherlands, with shorter duration of follow-up in The Netherlands compared to Australia. In a landmark analysis, over the period when more than 90% of patients in each region had been followed, the effects of colchicine were similar (Australia hazard ratio [HR] 0.58; 95% CI 0.34-0.97 vs The Netherlands HR 0.67; 95% CI 0.47-0.96).
Conclusions |
After examining several plausible explanations for the observed differences in the magnitude of treatment effect of colchicine between regions in the LoDoCo2 trial could be due to the differences in duration of follow-up but a substantial portion of the differences remain unexplained.
Clinical Trial Registration |
Mappa
Vol 278
P. 186-194 - dicembre 2024 Ritorno al numero
Articolo precedente
- Trends in cancer and heart failure related mortality in adult US population: A CDC WONDER database analysis from 1999 to 2020
- Shurjeel Uddin Qazi, Arsalan Hamid, Huzaifa Ul Haq Ansari, Michel G. Khouri, Markus S. Anker, Michael E. Hall, Stefan D. Anker, Javed Butler, Muhammad Shahzeb Khan
- Enrollment strategies in the era of digital revolution: Experience from a remote health management program
- Shahzad Hassan, Lee-Shing Chang, Daniel Gabovitch, Jacqueline Chasse, Gretchen Stern, Caitlin Colling, David Zelle, Christopher P. Cannon, Deborah Wexler, Benjamin M. Scirica, Alexander J. Blood
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?